Our Product
We aim to develop new generation of autologous or allogeneic CAR-T cell therapy to treat hematological or solid tumors. CAR-T combines techniques of cell, gene and immunology, which represents the most cutting-edge cancer treatment. Currently, CAR-T cell therapy achieves impressive efficacy in treating leukemia, lymphoma and multiple-myeloma, showing response rate over 80% among those relapsed/refractory patients.
